161 related articles for article (PubMed ID: 35679521)
1. Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience.
Seitter SJ; McClelland PH; Ahlman MA; Goff SL; Yang JC; McIntyre L; Rosenberg SA; Kochenderfer JN; Brudno JN
Leuk Lymphoma; 2022 Oct; 63(10):2469-2473. PubMed ID: 35679521
[No Abstract] [Full Text] [Related]
2. CAR T-cells in relapsed Burkitt lymphoma - a promising test drive in a rare disease.
Erika Haydu J; Abramson JS
Leuk Lymphoma; 2022 Oct; 63(10):2263-2264. PubMed ID: 35856474
[No Abstract] [Full Text] [Related]
3. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
Front Immunol; 2022; 13():879983. PubMed ID: 35669773
[TBL] [Abstract][Full Text] [Related]
4. Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma.
Liu Y; Deng B; Hu B; Zhang W; Zhu Q; Liu Y; Wang S; Zhang P; Yang Y; Yang J; Zheng Q; Yu X; Gao Z; Zhou C; Han W; Yang J; Jin L; Tong C; Chang AH; Zhang Y
Blood Adv; 2022 Feb; 6(3):717-730. PubMed ID: 34521107
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL.
Qiu Y; Wan CL; Xu MZ; Zhou HX; Liu MJ; Gong WJ; Kang LQ; Sun AN; Yu L; Wu DP; Qian CS; Xue SL
Blood Cancer J; 2023 May; 13(1):66. PubMed ID: 37137904
[No Abstract] [Full Text] [Related]
6. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract][Full Text] [Related]
7. Sequential anti-CD19, 22, and 20 autologous chimeric antigen receptor T-cell (CAR-T) treatments of a child with relapsed refractory Burkitt lymphoma: a case report and literature review.
Du J; Zhang Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1575-1582. PubMed ID: 32222815
[TBL] [Abstract][Full Text] [Related]
8. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
9. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
12. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
13. Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Wu JF; Abid H; Szabo A; Abid MB
Br J Haematol; 2023 Dec; 203(5):e117-e120. PubMed ID: 37814795
[No Abstract] [Full Text] [Related]
14. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
15. Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel.
Galletta TJ; Rubinstein JD; Krupski C; Nelson AS; Khoury R; Dandoy CE; Davies SM; Phillips CL
Pediatr Blood Cancer; 2023 May; 70(5):e30271. PubMed ID: 36815392
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
18. Managing the toxicities of CAR T-cell therapy.
Neelapu SS
Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
[TBL] [Abstract][Full Text] [Related]
19. CD19 CAR T-cell therapy demonstrates activity against extramedullary disease in pediatric patients with B-ALL.
Epperly R; Shulkin BL; Bag AK; Cheng C; Inaba H; Lucas JT; Naik S; Triplett BM; Gottschalk S; Talleur AC
Blood Adv; 2023 Oct; 7(20):6320-6324. PubMed ID: 37595052
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of additional CD19-targeted cellular therapy in relapsed/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse.
Agrawal V; Salhotra A; Song J; Gu Z; Stein AS; Marcucci G; Forman SJ; Pullarkat V; Aldoss I
Am J Hematol; 2023 Feb; 98(2):E38-E40. PubMed ID: 36413124
[No Abstract] [Full Text] [Related]
[Next] [New Search]